Documents
Médias
AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Editeur
AstraZeneca
Publications
(
1
)